Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of “Buy” by Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $29.50.

Several research firms recently weighed in on CPRX. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares in the company, valued at approximately $7,012,367.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 201,058 shares of company stock valued at $4,018,188 in the last 90 days. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Catalyst Pharmaceuticals by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company’s stock valued at $119,694,000 after purchasing an additional 73,930 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 15.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,719 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of Catalyst Pharmaceuticals by 76.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 81,017 shares of the biopharmaceutical company’s stock valued at $1,291,000 after acquiring an additional 35,066 shares during the period. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares during the period. Finally, Toth Financial Advisory Corp raised its stake in Catalyst Pharmaceuticals by 1,252.0% in the 1st quarter. Toth Financial Advisory Corp now owns 33,800 shares of the biopharmaceutical company’s stock worth $539,000 after acquiring an additional 31,300 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $21.46 on Friday. The company has a market capitalization of $2.53 billion, a PE ratio of 39.74, a P/E/G ratio of 3.18 and a beta of 0.76. The company has a 50 day moving average price of $20.27 and a 200-day moving average price of $17.50. Catalyst Pharmaceuticals has a fifty-two week low of $11.89 and a fifty-two week high of $21.85.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The company had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. On average, analysts forecast that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.